Results 81 to 90 of about 3,353 (184)

Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains

Infection and Drug Resistance, 2022
Ryota Ito, Masato Kawamura, Takumi Sato, Shigeru Fujimura Tohoku Medical and Pharmaceutical University, Division of Clinical Infectious Diseases & Chemotherapy, Sendai, Miyagi, JapanCorrespondence: Ryota Ito, Tohoku Medical and Pharmaceutical University,
Ito R, Kawamura M, Sato T, Fujimura S
doaj  

Various Bacillus and Paenibacillus Spp. Isolated From Soil Produce Compounds With Potent Antimicrobial Activity Against Clinically Relevant Pathogens

MicrobiologyOpen, Volume 14, Issue 6, December 2025.
This study identified soil‐derived Bacillus and Paenibacillus strains with broad‐spectrum antimicrobial activity, including 97% inhibition of CREs by Paenibacillus profundus. Genome mining revealed biosynthetic gene clusters (NRPSs, PKSs, RiPPs) linked to antimicrobial production, highlighting their potential in combating antibiotic resistance. Created
Michael Moran, Hogan Turner, Joseph Yanchar, Joshua Preece, Gene Ahlborn, Richard Robison   +5 more
wiley   +1 more source

Mechanistic basis for inhibition of the extended‐spectrum β‐lactamase GES‐1 by enmetazobactam and tazobactam

FEBS Letters, Volume 599, Issue 22, Page 3284-3300, November 2025.
Antimicrobial resistance (AMR) is of huge importance, resulting in over 1 million deaths each year. Here, we describe how a new drug, enmetazobactam, designed to help fight resistant bacterial diseases, inhibits a key enzyme (GES‐1) responsible for AMR. Our data show it is a more potent inhibitor than the related tazobactam, with high‐level computation
Michael Beer, Philip Hinchliffe, Marko Hanževački, Christopher R. Bethel, Catherine L. Tooke, Marc W. Van der Kamp, Krisztina M. Papp‐Wallace, Robert A. Bonomo, Stuart Shapiro, Adrian J. Mulholland, James Spencer   +10 more
wiley   +1 more source

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence

Life
(1) Background: Infections caused by multidrug-resistant (MDR) bacteria represent one of the major global public health problems of the 21st century. Beta-lactam antibacterial agents are commonly used to treat infections due to Gram-negative pathogens. New β-lactam/β-lactamase inhibitor combinations are urgently needed.
Sansone, Pasquale, Giaccari, Luca Gregorio, Di Flumeri, Giusy, Pace, Maria Caterina, Pota, Vincenzo, Coppolino, Francesco, Brunetti, Simona, Aurilio, Caterina   +7 more
openaire   +4 more sources

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

Microbiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang, Jin Yang Baek, Jae-Hoon Ko, Sun Young Cho, Keon Young Lee, Young Ho Lee, Jinyoung Yang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee, Kyungmin Huh, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck   +13 more
doaj   +1 more source

Susceptibility to Imipenem/Relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii Isolates from Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 to 2018

Infection and Drug Resistance, 2021
Hui Zhang,1,* Peiyao Jia,1,2,* Ying Zhu,1,2,* Ge Zhang,1 Jingjia Zhang,1 Wei Kang,1 Simeng Duan,1 Weijuan Zhang,3 Qiwen Yang,1 Yingchun Xu1 1Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking ...
Zhang H, Jia P, Zhu Y, Zhang G, Zhang J, Kang W, Duan S, Zhang W, Yang Q, Xu Y   +9 more
doaj  

Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance

Journal of Antimicrobial Chemotherapy, 2019
Abstract Objectives Imipenem/relebactam, an investigational β-lactam/β-lactamase inhibitor combination for treatment of Gram-negative infections, and comparators including ceftazidime/avibactam, piperacillin/tazobactam and colistin were tested for activity against representative carbapenemase ...
Jessica Carpenter, Nick Neidig, Alex Campbell, Tanner Thornsberry, Taylor Truex, Tiffany Fortney, Yunliang Zhang, Karen Bush   +7 more
openaire   +2 more sources

In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa [PDF]

, 2019
[eng] Pseudomonas aeruginosa, is a major cause of nosocomial and chronic infections, being considered a paradigm of antimicrobial resistance development.
Gomis Font, Maria Antonia
core  

The Rapid CarbaLux Combination Test to Uncover Bacterial Resistance and Heteroresistance Prior to Antibiotic Treatment

Diagnostics
Background/Objectives: In this proof-of-concept study, the objective was to evaluate the phenotypic CarbaLux combination rapid test in terms of guiding the therapy of infections caused by multidrug-resistant Gram-negative bacteria with carbapenemase ...
Hans Rudolf Pfaendler, Hans-Ulrich Schmidt   +1 more
doaj   +1 more source

Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains [PDF]

, 2018
Relebactam is an important beta-lactamase inhibitor for certain aerobic organisms, but alone it has no antianaerobic activity, with most anaerobes having MICs of ≥32 μg/ml with the exception of a very few strains.
Ellie J. C. Goldstein, C. Vreni Merriam, Citron, Diane M, Merriam, C Vreni, Eliza Leoncio, Tyrrell, Kerin L, Diane M. Citron, Kerin L. Tyrrell, Goldstein, Ellie JC, Leoncio, Eliza   +9 more
core   +1 more source